Materials for tissue regeneration within systemically altered bone (Werkstoffe für die Geweberegenration im systemisch erkrankten Knochen)
For the first time, our results allow meeting a second major clinical challenge, a local treatment of multiple myeloma in specific situations per se: Material properties and compounds released locally at high concentrations shall first eliminate residual myeloma cells after successful treatment, and secondly bring resistant myeloma cells under control locally, thereby avoiding further bone destruction. Furthermore, results in the second funding period lay the basis for a whole-body-detection of minimum numbers of tumor cells.
Unique features of our SFB/TRR 79 initiative are: i) bone substitute materials and metallic implants are developed taking into account biomechanics, architecture and altered remodeling in systemically dis-eased bone in relation to the underlying disease (“etiology-adapted”). ii) Synergistically, bone defects in osteoporosis and malignant diseases are investigated simultaneously. iii) For the first time, materials are specifically developed for a local treatment of multiple myeloma. iv) Within our concept, the life sciences present themselves “at the service” of material development, simultaneously integrating state-of-the-art techniques in molecular biology and imaging. Investigations in men, animal experiment, and cell culture are linked and feed back to material development. At the same time, they investigate own basic research questions related to specific topics, e.g. immunological elements of osteoporosis and multiple myeloma pathogenesis. The complexity of this challenge prerequisites an interdisciplinary collaboration of a synergistically acting research-consortium of “critical mass” (as the SFB/Transregio-initiative). Here we combine the complementary expertise at the different locations: Dresden – material science (bone substitute material and implants), Gießen – non-malignant bone defects (pathophysiology of osteoporosis, imaging) and animal models, and Heidelberg – life sciences, imaging and multiple myeloma.
More information can be found here